Captrust Financial Advisors Arvinas, Inc. Transaction History

Captrust Financial Advisors

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 16, 2022	SELL	$36.01 - $74.24 $3,781 - $7,795	-105 Reduced 48.61%	111 $5,000
Q1 2022 May 16, 2022	SELL	$60.27 - $81.57 $1,687 - $2,283	-28 Reduced 11.48%	216 $15,000
Q4 2021 Feb 14, 2022	SELL	$65.85 - $96.21 $2,963 - $4,329	-45 Reduced 15.57%	244 $20,000
Q3 2021 Nov 16, 2021	BUY	$73.2 - $107.87 $9,296 - $13,699	127 Added 78.4%	289 $24,000
Q2 2021 Aug 16, 2021	BUY	$60.45 - $84.26 $3,082 - $4,297	51 Added 45.95%	162 $12,000
Q1 2021 May 17, 2021	BUY	$58.19 - $91.37 $6,459 - $10,142	111 New	111 $7,000

229

68.4M

226K

285K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $1.02B
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.